Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043911 | 0.78 | ALDH1A1 (0.41) | IDO1SMN1; SMN2 | |
| SCHEMBL1043912 | 0.78 | ALDH1A1 (0.41) | IDO1SMN1; SMN2 | |
| SCHEMBL20152019 | 0.78 | GSK3B (0.43) | GSK3BDYRK1AMKNK1MKNK2CHEK1 | |
| SCHEMBL20151744 | 0.75 | ALDH1A1 (0.32) | MKNK1MKNK2SMN1; SMN2GRNSORT1 | |
| SCHEMBL18228565 | 0.74 | PKM (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL1046990 | 0.74 | CES2 (0.34) | IDO1 | |
| SCHEMBL1046991 | 0.74 | CES2 (0.34) | IDO1 | |
| SCHEMBL18239365 | 0.74 | PKM (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL18228566 | 0.74 | PKM (0.43) | SMN1; SMN2RAB9A | |
| SCHEMBL20151712 | 0.71 | VNN1 (0.43) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| WO-2018087021-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | PFKFB1, PFKFB2, PFKFB4 | GSK3B 965/4885DYRK1A 552/4885MKNK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.